AAC
Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ewart, G. D.
Right arrow Articles by Gage, P. W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ewart, G. D.
Right arrow Articles by Gage, P. W.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, June 2004, p. 2325-2330, Vol. 48, No. 6
0066-4804/04/$08.00+0     DOI: 10.1128/AAC.48.6.2325-2330.2004
Copyright © 2004, American Society for Microbiology. All Rights Reserved.

Potential New Anti-Human Immunodeficiency Virus Type 1 Compounds Depress Virus Replication in Cultured Human Macrophages

Gary D. Ewart,1* Najla Nasr,2 Hassan Naif,2 Graeme B. Cox,3 Anthony L. Cunningham,2 and Peter W. Gage3

Biotron Limited,1 John Curtin School of Medical Research, Australian National University, Canberra, ACT 2601,3 Westmead Millenium Institute, Westmead, NSW 2145, Australia2

Received 3 November 2003/ Returned for modification 6 January 2004/ Accepted 20 February 2004

We report that the amiloride analogues 5-(N,N-hexamethylene)amiloride and 5-(N,N-dimethyl)amiloride inhibit, at micromolar concentrations, the replication of human immunodeficiency virus type 1 (HIV-1) in cultured human blood monocyte-derived macrophages. These compounds also inhibit the in vitro activities of the HIV-1 Vpu protein and might represent lead compounds for a new class of anti-HIV-1 drugs.

* Corresponding author. Mailing address: Biotron Limited, LPO Box A315, Eggleston Rd., Australian National University, Canberra, ACT 2601, Australia. Phone: 612 61258080. Fax: 612 61258070. E-mail: gewart{at}biotron.com.au.

Antimicrobial Agents and Chemotherapy, June 2004, p. 2325-2330, Vol. 48, No. 6
0066-4804/04/$08.00+0     DOI: 10.1128/AAC.48.6.2325-2330.2004
Copyright © 2004, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:



Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
Clin. Vaccine Immunol. Clin. Microbiol. Rev.
J. Clin. Microbiol. ALL ASM JOURNALS

Copyright © 2004 by the American Society for Microbiology. All rights reserved.